Oncology
Ositab is one of the recommended brands in the oncology division that manage the EGFR mutated NSCLC (Non-small cell lung cancer) in patients who have already progressed on or after taking EGFR TKI therapy. It comes in two dose forms and is prescribed accordingly based on the clinical condition of the patient. Click on the appropriate link below to view more details like uses, composition, and description of the products.
